Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers
A randomized double-blind clinical trial
Keywords:
Attention-deficit hyperactivity disorder, Efficacy, Haloperidol, RisperidoneAbstract
Background: Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%.
Objective: To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children.
Methods: In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners’ Parent Rating Scale (CPRS-48), Children’s Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher’s exact tests in the SPSS 19.
Results: During the 6 weeks, the decline in points was seen in Conner’s rating scale and in ADHD-RS score in Risperidone and Haloperidol groups (p<0.001). On the CGAS scale, an increase of performance in both groups for six weeks was statistically significant (p<0.001). In the scales of ADHD-RS and CPRS-48, no statistically significant difference was observed between the two treatment groups; i.e., in terms of reducing the rate during weeks of two, four, and six (p>0.05).
Conclusions: Haloperidol and Risperidone possibly can be an acceptable treatment choice in the ADHD treatment of 3- to 6-year-old children.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015082623766N1.
Funding: This work was financially supported by grant (ref. no.: U-93130) from the vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences.
References
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a
systematic review and metaregression analysis. Am J Psychiatry. 2007; 164(6): 942-8. doi:
1176/ajp.2007.164.6.942. PMID: 17541055.
Ardalan G, Farhoud DD, Shah Mohammadi D. Hyperactivity, attention and concentration deficit in
preschool children. Iranian Journal of Pediatrics. 2002; 12(4): 53-6.
Tashakori A, Afkandeh R. Prevalence of ADHD Symptoms amonge Male Preschoolers Based on Different
Informants in Ahvas City of Iran. ISRN pediatrics. 2011; 2011: 709653. doi: 10.5402/2011/709653. PMID:
, PMCID: PMC3263576.
Ferguson JH. National Institutes of Health Consensus Development Conference Statement: Diagnosis and
treatment of attention-deficit/hyperactivity disorder (ADHD). Journal of the American Academy of Child
& Adolescent Psychiatry. 2000; 39(2): 182-93. doi: 10.1097/00004583-200002000-00018.
Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity
disorder. Pediatrics. 2000; 105(5): 1158-70. doi: 10.1542/peds.105.5.1158. PMID: 10836893.
Visser SN, Bitsko RH, Danielson ML, Ghandour RM, Blumberg SJ, Schieve LA, et al. Treatment of
Attention Deficit/Hyperactivity Disorder among Children with Special Health Care Needs. J Pediatr. 2015;
(6): 1423-30. doi: 10.1016/j.jpeds.2015.02.018. PMID: 25841538, PMCID: PMC4469986.
Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of
methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006; 45(11):
-303. doi: 10.1097/01.chi.0000235082.63156.27. PMID: 17028508.
Rosenberg D, Gershon S. Pharmacotherapy for child and adolescent psychiatric disorders: CRC Press;
Riahi F, Tehrani-Doost M, Shahrivar Z, Alaghband-Rad J. Efficacy of reboxetine in adults with attention‐
deficit/hyperactivity disorder: A randomized, placebo‐controlled clinical trial. Hum Psychopharmacol.
; 25(7‐8): 570-6. doi: 10.1002/hup.1158. PMID: 21312292.
Riahi F, Tashakori A, Izadi-Mazidi S, Salehi-Veysi M. Effectiveness of Reboxetine in Treatment of
Outpatient Children and Adolescents with Attention Deficit-Hyperactivity Disorder with Comorbid
Anxiety Disorders. Iran J Psychiatry. 2013; 8(4): 195. PMID: 25628714, PMCID: PMC4281655.
Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD:
translation between clinical and preclinical studies. Clin Psychol Rev. 2006; 26(4): 379-95. doi:
1016/j.cpr.2006.01.001. PMID: 16504359, PMCID: PMC1892795.
O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology,
mechanisms and management. CNS Drugs. 2009; 23(2): 157-70. doi: 10.2165/00023210-200923020- 00005. PMID: 19173374.
Goto Y, Otani S, Grace AA. The Yin and Yang of dopamine release: a new perspective.
Neuropharmacology. 2007; 53(5): 583-7. doi: 10.1016/j.neuropharm.2007.07.007. PMID: 17709119,
PMCID: PMC2078202.
Sikstrom S, Soderlund G. Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder.
Psychol Rev. 2007; 114(4): 1047-75. doi: 10.1037/0033-295X.114.4.1047. PMID: 17907872.
Braun A, Laruelle M, Mouradian M. Interactions between D1 and D2 dopamine receptor family agonists
and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical
implications. Journal of neural transmission. 1997; 104(4-5): 341-62. doi: 10.1007/BF01277656. PMID:
Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. Breakthrough dopamine supersensitivity during
ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007; 27(11): 2979-86.
doi: 10.1523/JNEUROSCI.5416-06.2007. PMID: 17360921.
Owen R, Owen F, Poulter M, Crow TJ. Dopamine D 2 receptors in substantia nigra in schizophrenia. Brain
research. 1984; 299(1): 152-4. doi: 10.1016/0006-8993(84)90798-4.
Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation
antipsychotics in a state Medicaid pediatric population, 2001–2005. Psychiatr Serv. 2010; 61(2): 123-9.
doi: 10.1176/ps.2010.61.2.123. PMID: 20123816.
Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in
children and adolescents. J Child Adolesc Psychopharmacol. 2004; 14(3): 372-94. doi:
1089/cap.2004.14.372. PMID: 15650494.
Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in
children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008; 4(1): 203-7. doi:
2147/NDT.S1992. PMID: 18728799, PMCID: PMC2515893.
Seida JC, Schouten JR, Mousavi SS, Hamm M, Beaith A, Vandermeer B, et al. First-and second-generation
antipsychotics for children and young adults. 2012.
Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, et al. Off-label use of atypical
antipsychotics: an update. 2011. PMID: 22132426.
Brock SE, Clinton A. Diagnosis of attention-deficit/hyperactivity disorder (AD/HD) in childhood: A
review of the literature. The California School Psychologist. 2007; 12(1): 73-91. doi:
1007/BF03340933.
Shayan A ST, Beaming L, yousefi F. Normalization factor analysis and reliability of the short form of
special conners parent rating scale for children in Shiraz city. J of psychological studies. 2007; 3(3): 97- 120.
Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, et al. Bupropion SR vs,
methylphenidate vs, placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry.
; 13(3): 129-34. doi: 10.3109/10401230109148958. PMID: 11791949.
Lundh A, Kowalski J, Sundberg CJ, Gumpert C, Landén M. Children's Global Assessment Scale (CGAS)
in a naturalistic clinical setting: Inter-rater reliability and comparison with expert ratings. Psychiatry Res.
; 177(1): 206-10. doi: 10.1016/j.psychres.2010.02.006. PMID: 20334931.
Kutcher SP, Lauria-Horner BA, MacLaren CM, Bujas-Bobanovic M. Practical child and adolescent
psychopharmacology: Cambridge University Press; 2002. doi: 10.1017/CBO9780511543920.
Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, et al. The Texas Children's
Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment
of Childhood Attention-Deficit/Hyperactivity Disorder, Part I. Journal of the American Academy of Child
& Adolescent Psychiatry. 2000; 39(7): 908-19. doi: 10.1097/00004583-200007000-00021.
Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children
with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001; 40(8): 887-94. doi:
1097/00004583-200108000-00009. PMID: 11501687.
Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E. Comparison of long-term efficacy and
safety of risperidone and haloperidol in children and adolescents with autistic disorder. Eur Child Adolesc
Psychiatry. 2008; 17(4): 217-25. doi: 10.1007/s00787-007-0656-6. PMID: 18026891.
Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with
pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003; 64(9): 1039-47. doi:
4088/JCP.v64n0909. PMID: 14628979.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
